Enbrel

Enbrel
Name	Enbrel

Enbrel is a medication used to treat various inflammatory conditions, including Rheumatoid Arthritis, Psoriatic Arthritis, and Plaque Psoriasis. It is developed by Amgen and Pfizer and has been approved by the US Food and Drug Administration (FDA) for the treatment of several diseases, including Ankylosing Spondylitis and Juvenile Idiopathic Arthritis. Enbrel has been shown to be effective in reducing symptoms and slowing disease progression in patients with these conditions, as demonstrated in clinical trials conducted by National Institutes of Health (NIH) and published in The New England Journal of Medicine. The medication has also been used in combination with other therapies, such as Methotrexate, to enhance its efficacy.

Introduction

Enbrel is a Tumor Necrosis Factor (TNF) inhibitor, which works by blocking the action of Tumor Necrosis Factor-Alpha (TNF-α), a protein involved in the inflammatory response. This mechanism of action is similar to that of other TNF inhibitors, such as Adalimumab and Infliximab, which are used to treat a range of inflammatory conditions, including Crohn's Disease and Ulcerative Colitis. Enbrel is administered via subcutaneous injection, typically once or twice a week, and has been shown to be well-tolerated in most patients, with a safety profile similar to that of other biologic therapies, such as Etanercept and Abatacept. The development of Enbrel was supported by research conducted at Stanford University and University of California, San Francisco.

Medical_uses

Enbrel is approved for the treatment of several inflammatory conditions, including Rheumatoid Arthritis, Psoriatic Arthritis, and Plaque Psoriasis. It is also used to treat Ankylosing Spondylitis and Juvenile Idiopathic Arthritis, and has been shown to be effective in reducing symptoms and slowing disease progression in patients with these conditions, as demonstrated in clinical trials conducted by Columbia University and published in The Lancet. Enbrel has also been used in combination with other therapies, such as Cyclosporine and Azathioprine, to enhance its efficacy. The medication has been used to treat patients with Behçet's Disease and Sjögren's Syndrome, and has been shown to be effective in reducing symptoms and improving quality of life, as reported in studies published in Arthritis & Rheumatology and The Journal of Rheumatology.

Mechanism_of_action

Enbrel works by blocking the action of Tumor Necrosis Factor-Alpha (TNF-α), a protein involved in the inflammatory response. TNF-α is a key mediator of inflammation, and its blockade has been shown to reduce inflammation and slow disease progression in patients with inflammatory conditions, as demonstrated in research conducted at Harvard University and University of Oxford. Enbrel binds to TNF-α, preventing it from interacting with its receptors on the surface of cells, and thereby reducing the production of pro-inflammatory cytokines, such as Interleukin-1 and Interleukin-6. This mechanism of action is similar to that of other TNF inhibitors, such as Adalimumab and Infliximab, which are used to treat a range of inflammatory conditions, including Crohn's Disease and Ulcerative Colitis, as reported in studies published in Gastroenterology and Inflammatory Bowel Diseases.

Side_effects

Enbrel has been associated with several side effects, including Injection Site Reactions, Upper Respiratory Tract Infections, and Headache. The medication has also been linked to an increased risk of Serious Infections, such as Pneumonia and Cellulitis, particularly in patients with underlying medical conditions, such as Diabetes Mellitus and Chronic Obstructive Pulmonary Disease. Enbrel has also been associated with an increased risk of Lymphoma and other Malignancies, although the exact mechanism of this association is not fully understood, as reported in studies published in The Journal of the American Medical Association and Blood. The safety profile of Enbrel is similar to that of other biologic therapies, such as Etanercept and Abatacept, which are used to treat a range of inflammatory conditions, including Rheumatoid Arthritis and Psoriatic Arthritis.

History

Enbrel was first approved by the US Food and Drug Administration (FDA) in 1998 for the treatment of Rheumatoid Arthritis. The medication was developed by Amgen and Pfizer, and was the first TNF inhibitor to be approved for the treatment of this condition. Since its initial approval, Enbrel has been approved for the treatment of several other inflammatory conditions, including Psoriatic Arthritis and Plaque Psoriasis. The development of Enbrel was supported by research conducted at Stanford University and University of California, San Francisco, and the medication has been shown to be effective in reducing symptoms and slowing disease progression in patients with these conditions, as demonstrated in clinical trials conducted by National Institutes of Health (NIH) and published in The New England Journal of Medicine.

Pharmacology

Enbrel is a recombinant Human Tumor Necrosis Factor Receptor (TNFR) fusion protein, which is produced by Chinese Hamster Ovary cells. The medication is administered via subcutaneous injection, typically once or twice a week, and has a half-life of approximately 70-100 hours. Enbrel has been shown to be well-tolerated in most patients, with a safety profile similar to that of other biologic therapies, such as Etanercept and Abatacept. The pharmacokinetics of Enbrel have been studied in patients with Rheumatoid Arthritis and Psoriatic Arthritis, and the medication has been shown to be effective in reducing symptoms and slowing disease progression in these patients, as reported in studies published in Arthritis & Rheumatology and The Journal of Rheumatology. The medication has also been used in combination with other therapies, such as Methotrexate and Cyclosporine, to enhance its efficacy.

Category:Medications